Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRACE STUDY: Tranexamic Acid in Subdural Hematoma
NCT05713630Phase 3Recruiting
- Sponsor
- Unity Health Toronto
- Start
- May 2026
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of tranexamic acid in subdural hematoma (SDH), sponsored by Unity Health Toronto. Started May 2026; status: recruiting.
02
Drugs
tranexamic acid
03
Conditions
subdural hematoma (SDH)
Beyond the preview
Go deeper on NCT05713630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05713630.